Skip to content

Corticosteroids and / or Arthrographic Distention in the Treatment of Adhesive Capsulitis

A Prospective Randomized 3-arm Trial Comparing Intra-articular Corticosteroid Injection vs Arthrographic Distention vs Arthrographic Distention Plus Intra-articular Corticosteroid Injection in the Treatment of Adhesive Capsulitis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01983527
Acronym
CADAC
Enrollment
132
Registered
2013-11-14
Start date
2013-12-31
Completion date
2015-11-30
Last updated
2013-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive Capsulitis, Frozen Shoulder

Keywords

Arthrographic distention, Hydrodilatation, Intra-articular corticosteroid injection

Brief summary

Arthrographic distention of the shoulder joint is an increasingly popular treatment option in the management of patients with frozen shoulder. Most have included the intra-articular injection of a corticosteroid as part of the procedure, but it is not known if this is necessary. It is also not known whether arthrographic distention using steroid and saline is better than intra-articular steroid injection alone. The purpose of this study is to determine whether there is an additional benefit in the combination of arthrographic distention plus intra-articular corticosteroid injection compared to arthrographic distention or intra-articular corticosteroid injection alone.

Interventions

PROCEDUREArthrographic distention

Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.

DRUGIntra-articular corticosteroid Depo Medrol

Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)

Sponsors

Universitaire Ziekenhuizen KU Leuven
CollaboratorOTHER
Imelda Hospital, Bonheiden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pain and stiffness in predominantly 1 shoulder for 4 weeks or longer * Restriction of passive motion of greater than 30° in 2 or more planes of movement (measured to onset of pain with goniometer)

Exclusion criteria

* Previous arthrographic distention and/or corticosteroid injection * Systemic inflammatory joint disease * Radiological evidence of osteoarthritis of the shoulder or fracture * Signs of a complete rotator cuff tear * Contraindications to arthrogram and/or distention * Lack of written informed consent

Design outcomes

Primary

MeasureTime frame
Shoulder pain and disability index(SPADI)4 weeks

Secondary

MeasureTime frameDescription
Shoulder pain and disability index (SPADI)weekly for a period of 3 months plus at follow-up (4 months and 12 months)
Overall pain scoreweekly for a period of 3 months, plus at follow-up (4 months and 12 months)Universal pain scale
Range of motion4 weeks, 4 months and 12 months* Total shoulder abduction (in degrees, measured with goniometer) * External rotation in neutral position (in degrees, measured with goniometer) * Hand behind back (highest reachable anatomical landmark)

Countries

Belgium

Contacts

Primary ContactRolf Symons, MD
rolf.symons@imelda.be+32(0)15/50.62.31

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026